Aytu Biopharma, Inc. AYTU
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -15.00K | -5.62M | -10.58M | 1.97M | -19.82M |
| Total Depreciation and Amortization | 1.12M | 1.12M | 885.00K | 803.00K | 1.46M |
| Total Amortization of Deferred Charges | 28.00K | 27.00K | 29.00K | 29.00K | 26.00K |
| Total Other Non-Cash Items | -416.00K | 2.10M | 9.36M | -3.39M | 19.43M |
| Change in Net Operating Assets | 3.69M | -1.81M | 3.98M | -23.00K | 1.70M |
| Cash from Operations | 4.41M | -4.18M | 3.68M | -618.00K | 2.80M |
| Capital Expenditure | -12.00K | 0.00 | -17.00K | -- | -17.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -3.00M |
| Cash from Investing | -12.00K | 0.00 | -17.00K | -- | -3.02M |
| Total Debt Issued | -1.35M | 1.34M | -5.80M | 5.81M | 892.00K |
| Total Debt Repaid | -3.45M | -464.00K | -465.00K | -464.00K | -464.00K |
| Issuance of Common Stock | -- | -- | -- | -- | 14.84M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | -3.05M | -2.28M |
| Cash from Financing | -4.80M | 872.00K | -6.26M | 2.30M | 12.99M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -407.00K | -3.31M | -2.61M | 1.68M | 12.78M |